Iksuda Therapeutics (Iksuda), which develops a new generation of enhanced antibody-drug conjugates (ADCs), is now activated in the tumor environment. Announced that it has exercised the option to obtain a worldwide exclusive right to develop class prodrug payloads from the University of Göttingen. This option exercise is a result of a partnership that has successfully demonstrated a set of payloads in ADC format. This highly powerful and selective set of payloads represents a powerful new class in ADC development with novel cytotoxicity that alkylates proteins. Going forward, Iksuda will move forward with development and commercialization, incorporating a tunable set of payloads into our ADC pipeline and payload "armory" to be potential targets for highly unmet needs for blood and solid tumors. We will work to create the best-in-class ADC therapeutic drug for cancer.

The partnership with the University of Göttingen is based on Iksuda's commitment to expanding the "armory" of the payload and optimizing the ADC design for the target antigen. The program confirmed that tumor-selective activation of these potent cytotoxic agents bound by Iksuda's stable binding technology (PermaLink ® ) is beneficial in expanding the therapeutic index of ADCs. .. While the focus of this field is primarily on intra-strand or inter-strand cross-linking, the novel mechanism of action of protein alkylation of these payloads offers the advantage of countering drug resistance mechanisms. Through the combination of PermaLink technology and protein alkylation prodrugs, we have the ability to increase tumor killing ability, along with improved safety index, while overcoming potential drug resistance of tumors, resulting in stronger ADC differentiation. We aim to realize possible development.

Iksuda targets difficult-to-treat B-cell cancers, including diffuse large B-cell lymphoma and Burkitt lymphoma, through a recently obtained CD19-targeted ADC license from LegoChem Biosciences (“LCB”). We have demonstrated the potential value of prodrug methods for the treatment of cancer. This ADC contains the DNA cross-linking payload, which is a prodrug of LCB, and preclinical data confirm a significant improvement in the therapeutic index compared to controls. In accordance with the expansion agreement, we have acquired the right to use LCB's prodrug payload platform for use on targets designated by Iksuda.

Dr. Dave Simpson, CEO of Iksuda Therapeutics, said: "The success of the partnership with the University of Göttingen, led by Professor Lutz Tietze, and the subsequent licensing agreement proves our continued efforts to build and improve the methods of ADC development. We have successfully addressed the industry-wide challenge of enabling treatment of patients with cancer. Iksuda has consistently leveraged our deep understanding of the ADC space to address areas of unmet clinical need. While embracing the challenge of targeting, we are focused on building a pipeline of next-generation ADCs with improved treatment indices through internal and external pipelines. "

Dr. Jens-Peter Horst, CEO of MBM Science Bridge, a technology transfer organization at the University of Göttingen, said: "This contract is a classic example of the successful transformation of years of academic research and development into a highly promising and innovative cancer treatment."

www.iksuda.com

The official version of this press release is the original language version. The translated language version is provided for the convenience of the reader and has no legal effect. When using the translated language version as a material, please compare it with the original language version, which is the only version that has legal effect.

Contacts
Zyme Communications
Lorna Cuddon
Tel: +44 (0) 7811 996 942
lorna.cuddon@zymecommunications.com

 

Source: businesswire.com

Report Abuse